Published in Arthritis Rheum on June 15, 2003
Sex-specific genetic architecture of human disease. Nat Rev Genet (2008) 4.01
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.48
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA (2011) 1.41
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 1.37
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) (2010) 1.32
A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) (2010) 1.29
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol (2009) 1.27
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol (2006) 1.08
Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics (2011) 1.06
Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum (2008) 1.05
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther (2013) 1.04
Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol (2008) 1.01
Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken) (2012) 1.00
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) (2014) 0.98
Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Pediatr Rheumatol Online J (2014) 0.97
The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum (2008) 0.92
Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. Curr Rheumatol Rep (2012) 0.90
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis (2013) 0.88
Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience. Pediatr Rheumatol Online J (2012) 0.86
Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease. Clin Immunol (2007) 0.84
Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil. An Bras Dermatol (2014) 0.83
The heterogeneity of juvenile myositis. Autoimmun Rev (2006) 0.83
MRI guided wire localization muscle biopsy in a child with juvenile dermatomyositis. Pediatr Rheumatol Online J (2013) 0.81
Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum (2012) 0.80
Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int (2010) 0.80
Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis. Clin Rheumatol (2014) 0.79
Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol (2013) 0.79
[Juvenile dermatomyositis]. Z Rheumatol (2006) 0.79
Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated. Arthritis Rheumatol (2015) 0.79
Vimovo™: (naproxen/esomeprazole magnesium) delayed-release tablets. P T (2010) 0.77
Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J (2014) 0.77
Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS One (2014) 0.76
Paediatric rheumatic disease: Defining clinically inactive disease in juvenile dermatomyositis. Nat Rev Rheumatol (2012) 0.76
[Dermatomyositis]. Z Rheumatol (2009) 0.75
Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol (2014) 0.75
Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci. PLoS Genet (2017) 0.75
Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J (2016) 0.75
Acute acalculous cholecystitis in a patient with juvenile dermatomyositis. BMJ Case Rep (2014) 0.75
On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. Commun Stat Theory Methods (2009) 0.75
Proceedings: Using Stem Cell Therapies to Reestablish Osteogenic Capability for Bone Regeneration. Stem Cells Transl Med (2015) 0.75
Acute Presentation of Juvenile Dermatomyositis with Subclinical Cardiac Involvement: A Rare Case. J Clin Diagn Res (2016) 0.75
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J (2017) 0.75
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr (2017) 0.75
Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol (2017) 0.75
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J (2017) 0.75
Juvenile dermatomyositis with Sjögren's syndrome. Clin Rheumatol (2007) 0.75
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Lifetime risks of cardiovascular disease. N Engl J Med (2012) 5.95
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Two-year follow-up results for Hip-Hop to Health Jr.: a randomized controlled trial for overweight prevention in preschool minority children. J Pediatr (2005) 2.85
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet (2008) 2.16
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Cancer screening in patients with systemic lupus erythematosus. J Rheumatol (2005) 1.75
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol (2013) 1.73
Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum (2003) 1.71
Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr (2006) 1.71
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol (2007) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Hip-Hop to Health Jr. for Latino preschool children. Obesity (Silver Spring) (2006) 1.61
History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum (2005) 1.58
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.48
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet (2010) 1.43
Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 1.42
Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol (2011) 1.41
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg (2008) 1.36
Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum (2008) 1.36
Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum (2009) 1.36
Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med (2006) 1.34
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) (2010) 1.32
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum (2009) 1.30
Results of a faith-based weight loss intervention for black women. J Natl Med Assoc (2005) 1.30
Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem (2005) 1.27
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol (2004) 1.21
Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation (2011) 1.20
25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.20
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum (2011) 1.19
Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet (2008) 1.16
Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet (2013) 1.14
Association of traditional risk factors with cardiovascular death across 0 to 10, 10 to 20, and >20 years follow-up in men and women. Am J Cardiol (2008) 1.13
Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.12
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Malignancy and autoimmunity. Curr Opin Rheumatol (2006) 1.11
A combined breast health/weight loss intervention for Black women. Prev Med (2005) 1.10
The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol (2002) 1.10
Obesity reduction black intervention trial (ORBIT): six-month results. Obesity (Silver Spring) (2008) 1.09
Obesity reduction black intervention trial (ORBIT): 18-month results. Obesity (Silver Spring) (2010) 1.09
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis (2009) 1.08
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol (2006) 1.08
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol (2010) 1.07
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis (2012) 1.07
Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics (2011) 1.06
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.06
Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum (2008) 1.05
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.05
Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol (2011) 1.04
Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol (2002) 1.04
Recruiting participants with peripheral arterial disease for clinical trials: experience from the Study to Improve Leg Circulation (SILC). J Vasc Surg (2009) 1.03
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
Obesity and risk factors for the metabolic syndrome among low-income, urban, African American schoolchildren: the rule rather than the exception? Am J Clin Nutr (2005) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol (2008) 1.01
Obesity Reduction Black Intervention Trial (ORBIT): design and baseline characteristics. J Womens Health (Larchmt) (2008) 1.01
Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum (2012) 1.01
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus. Arthritis Rheum (2011) 1.01
Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr (2010) 1.00
Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum (2010) 1.00
MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet (2013) 0.99
Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum (2012) 0.99
Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms. Autoimmun Rev (2005) 0.99
Reach-out: a family-based diabetes prevention program for African American youth. J Natl Med Assoc (2011) 0.98
Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. Arthritis Rheum (2011) 0.98
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum (2012) 0.98
Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum (2007) 0.97
The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol (2010) 0.97
Hip-Hop to Health Jr., an obesity prevention program for minority preschool children: baseline characteristics of participants. Prev Med (2003) 0.97
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Ann Rheum Dis (2012) 0.96
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum (2012) 0.96
Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol (2002) 0.96
ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol (2013) 0.95
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94
Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vasc Med (2009) 0.94
Systemic lupus and malignancies. Curr Opin Rheumatol (2012) 0.94